Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zai Lab Limited - American Depositary Shares (NQ: ZLAB )

26.72 +0.50 (+1.91%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Zai Lab Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?
Via The Motley Fool
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
NovoCure and Zai Lab report PANOVA-3 trial success with TTFields therapy, achieving significant survival benefits for pancreatic cancer patients. 
Via Benzinga
Why Zai Lab (ZLAB) Stock Is Trading Higher
Zai Lab shares are trading higher by 4% during Friday's session. The company priced a $200 million public offering. 
Via Benzinga
Despegar.com, Zai Lab, Bloom Energy And Other Big Stocks Moving Higher On Friday
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Zai Lab, A Top 6% Stock, Launched To A 16-Month High On Its 'Impressive' Results
The company is working on an antibody drug conjugate, which is like a smart bomb for cancer cells. 
Via Investor's Business Daily
Recap: Zai Lab Q4 Earnings
Via Benzinga
Earnings Scheduled For February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
What Happened With Zai Lab Stock?
Zai Lab Limited (NASDAQ: ZLAB) shares traded lower on Thursday. The stock has pulled back sharply from recent strength. 
Via Benzinga
UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Stitch Fix Reports Weak Earnings, Joins KB Home And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Why Is Zynex (ZYXI) Stock Down 24% Today?
Zynex stock is falling on Friday as ZYXI investor react to earnings misses and poor guidance for Q3 and the full year of 2024. 
Via InvestorPlace
Topics Earnings
Exposures Financial
Why Is DexCom (DXCM) Stock Down 38% Today?
DexCom stock is up on Friday as DXCM investors react to the company's latest earnings report and its lackluster 2024 guidance. 
Via InvestorPlace
Trade of the Day: Zai Lab (ZLAB) Stock Is a Possible Hidden Gem
A compelling hidden-gem opportunity, Zai Lab’s groundbreaking cancer therapeutic and discounted valuation could drive up ZLAB stock. 
Via InvestorPlace
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Saia, Annexon, Core Scientific And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Spectrum Brands Posts Upbeat Results, Joins AerSale, Sinclair, ICU Medical And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are a hot topic this morning and we've got traders covered with all of the news behind these movements on Thursday! 
Via InvestorPlace
ZLAB Stock Earnings: Zai Lab Beats EPS, Beats Revenue for Q1 2024
ZLAB stock results show that Zai Lab beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates... 
Via Talk Markets
One Good, One Bad News For Bristol Myers Squibb's Marketed Drugs: Details
Bristol Myers Squibb shares update on Phase 3 YELLOWSTONE trial for Zeposia (ozanimod) in Crohn's disease. Primary endpoint not met, safety consistent. Also, positive Phase 3 results for Krazati... 
Via Benzinga
Shhh! 7 Small-Cap Stocks That Can Double by 2025
Small-cap stocks have been hot and these shares discussed here are likely to heat up and double over the next year. 
Via InvestorPlace
Stock Disconnect Triggers Investor Exodus From CStone Pharma
Key Takeaways: CEO Jason Yang has increased his CStone stake multiple times over the past 18 months to 4.79% of outstanding shares, signaling confidence in the company 
Via Benzinga
Top 5 Health Care Stocks That Are Preparing To Pump In February
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Archer-Daniels-Midland, B. Riley Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Monday. Shares of Archer-Daniels-Midland Company (NYSE: ADM) fell sharply in today’s pre-market trading... 
Via Benzinga
Paychex Reports Downbeat Sales, Joins BlackBerry And Other Big Stocks Moving Lower On Thursday
U.S. stocks traded higher, with the Dow Jones index gaining around 200 points on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.